[Cannabis in Parkinson’s Disease: Hype or help?]

Fortschr Neurol Psychiatr. 2018 Jan 11. doi: 10.1055/s-0043-120668.
[Epub ahead of print]
[Article in German; Abstract available in German from the publisher]

Abstract

Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies. The prescription of medical marihuana is not restricted to specific symptoms and is therefore also valid for patients with Parkinson’s disease. From a legal perspective, patients who are seriously ill even have the right to be treated with cannabis if standard treatment methods are unsuccessful or result in unbearable side effects. This also applies even if only a slight chance of noticeable improvement is predicted as a result of the cannabis treatment. Bearing this in mind and due to an intense media coverage of this topic, more and more patients with Parkinson’s disease are requesting cannabis prescription, which is a challenging situation to their neurologists. This article provides an overview of the various cannabis products that can be prescribed, the different modes of administration and the available literature regarding motor- and non-motor symptoms in Parkinson’s disease. Furthermore, the authors state their opinion on which indications cannabinoids could be useful in treating patients with Parkinson’s disease or in which situation the patient could or even should be prescribed cannabinoids. Additionally, this article presents practical recommendations for the prescription of cannabinoids and patient counseling, e. g., on the effects of medical marijuana on driving capacity.

PMID: 29325182
DOI: 10.1055/s-0043-120668

Conflict of interest statement

Interessenkonflikt: Die Autoren geben an, dass kein Interessenkonflikt besteht.

Tags: , , ,